Barrett's esophagus: proton pump inhibitors and chemoprevention II

Authors :: Joel E, Richter
Roberto, Penagini
Andrea, Tenca
Daniel, Pohl
Katerina, Dvorak
Aaron, Goldman
Edoardo, Savarino
Patrizia, Zentilin
Vincenzo, Savarino
Joshua T, Watson
Roy K H, Wong
Fabio, Pace
Valentina, Casini
David A, Peura
Shoshana Joy, Herzig
Takeshi, Kamiya
Iva, Pelosini
Carmelo, Scarpignato
David, Armstrong
Kenneth R, DeVault
Paolo, Bechi
Antonio, Taddei
Giancarlo, Freschi
Maria Novella, Ringressi
Duccio Rossi, Degli'Innocenti
Francesca, Castiglione
Emmanuella, Masini
Richard H, Hunt
Publication Year :: 2011
Publisher :: BLACKWELL SCIENCE PUBL, OSNEY MEAD, OXFORD OX2 0EL, ENGLAND, 2011.
Abstract: The following on proton pump inhibitors (PPIs) and chemoprevention in relation to Barrett's esophagus includes commentaries on 48-h pH monitoring, pH-impedence, bile acid testing, dyspepsia, long/short segment Barrett's esophagus, nonerosive reflux disease (NERD), functional heartburn, dual-release delivery PPIs, immediate-release PPIs, long-term PPI use, prokinetic agents, obesity, baclofen, nocturnal acid breakthrough, nonsteroidal anti-inflammatory drugs (NSAIDs), and new PPIs.

Subjects :: Barrett Esophagus
Barrett's esophagus
Treatment Outcome
GASTROESOPHAGEAL-REFLUX
proton pump inhibitors
Humans
Chemoprevention
digestive system diseases
drug therapy, Chemoprevention, Humans, Monitoring
Physiologic, Proton Pump Inhibitors
therapeutic use, Treatment Outcome
Monitoring, Physiologic

Tools